Portfolio Overview
Ownership & Control Structure
What Companies Does Andrew Dudum Own?
Andrew Dudum controls Hims & Hers Health through its supervoting share structure while holding a much smaller economic interest than his voting percentage suggests. The 2026 proxy reported 87.73% of total voting power as of April 16, reflecting Class V shares entitled to 175 votes each. We identify the listed healthcare business as his principal verified controlled holding, rather than describing him as the owner of nearly nine-tenths of its financial value or assuming that ordinary shareholders lack an economic interest.
Hims and Hers are consumer brands inside the same public parent. Eucalyptus, YourBio Health, ZAVA and Livewell also sit within its acquired operating structure rather than becoming businesses Dudum purchased personally with a separate individual check. YourBio’s merger closed in January 2026, and Eucalyptus was acquired in June. The company’s filings assigned acquisition-date accounting consideration of $153 million and $968.5 million respectively, figures that describe corporate transactions and are not amounts added to Dudum’s own personal wealth.
Andrew Dudum also helped co-found Atomic, the startup studio that developed companies including Bungalow, Homebound, TalkIQ and Terminal. His official biography establishes those venture-creation roles, but it does not give a present individual ownership breakdown for each company. Those businesses should not all be represented as controlled holdings simply because he helped develop them through the studio. The same principle applies to advisory relationships: being associated with a venture investor does not establish personal ownership of its complete portfolio.
His economic exposure to Hims & Hers Health includes directly held shares, trust holdings and equity awards described in the proxy, each with different implications for liquidity. The disclosed voting percentage is a dated governance measure, not a continuously current market valuation. Dudum’s portfolio is therefore best understood as a founder-controlled digital-health platform with a broader venture-building history. The acquired subsidiaries expand that platform’s reach, while public shareholders and other security holders retain their own claims on its financial results.
Portfolio Analysis
Dudum’s portfolio has a concentrated economic center even though the company he controls now operates across brands and geographies. Hims & Hers Health contains the acquisitions and customer relationships that drive the public equity’s value. We regard its internal expansion as diversification of operations, not a diversified personal portfolio comparable to several independent listed holdings. A change in sentiment, regulation or profitability at the parent can affect the value of many underlying initiatives simultaneously because investors price them through the same security.
The Eucalyptus and YourBio transactions broadened capabilities in 2026 but also directed substantial capital toward the same healthcare ecosystem. Their respective accounting purchase prices of $968.5 million and $153 million cannot be counted as extra assets owned outside Dudum’s listed stake. The economic benefit or loss from those purchases flows through the parent’s future results and capital structure. That makes integration and the return on acquisition spending more relevant than simply treating the subsidiary names as separate sources of personal wealth.
Atomic’s history gives Andrew Dudum connections to businesses in other sectors, including housing and enterprise services. His official biographies describe work involving Terminal, Bungalow, Homebound and TalkIQ. They do not establish a complete current allocation of personal capital to those ventures. Including every studio company as his individual investment would overstate the breadth of disclosed ownership and blur the difference between helping create a business through an organization and retaining a separately documented present claim on its eventual proceeds.
The public stake offers potential liquidity that private founder holdings may lack, but supervoting control and ordinary economic exposure must still be separated. The April 2026 proxy’s 87.73% voting figure does not provide an equivalent diversification cushion or a claim to that percentage of profits. Dudum remains heavily exposed to how a single public platform converts growth into earnings. Its range of activities can create several operating opportunities while leaving the founder’s principal disclosed financial position sensitive to a common market valuation and execution record.
Business Profile
Hims & Hers combines digital customer acquisition, clinical access and recurring product relationships across several health categories. In its November 2026 results, the company reported approximately $890 million of third-quarter revenue and nearly 2.8 million subscribers. That scale makes retention, product mix and fulfillment economically consequential. We assess the business through the contribution generated from serving customers after the cost of care, products and marketing, rather than assuming that subscription growth alone establishes the profitability of every customer relationship or treatment category.
The third-quarter filing reported a 57% gross margin, down from 74% a year earlier. Revenue growth can therefore coexist with pressure on the amount retained before operating expenses. A larger platform is not automatically a higher-quality business if a changing treatment mix or cost structure consumes more of each sales dollar. For Dudum, the relevant ownership exposure is to the residual earnings capacity after these shifts, making margin behavior an essential counterweight to subscriber counts and the breadth of the brand’s consumer reach.
Acquiring Eucalyptus added an international operating platform rather than merely another marketing name. The June 2026 closing expanded geographic reach and brought local capabilities into the group. YourBio added blood-sampling technology through a separate transaction earlier in the year. Those purchases can deepen the customer offering, but they also introduce integration work and financial obligations. The businesses need to produce value inside the wider system, rather than just increasing the acquisition total or the number of countries mentioned in corporate announcements.
Andrew Dudum’s venture-studio background explains an emphasis on building a platform with multiple growth initiatives. At public-company scale, however, that approach must be matched by operating discipline, reliable clinical relationships and appropriate product availability. Marketing can attract a customer, but repeat engagement depends on the service delivered. His business model is consequently broader than an online storefront, with technology, care access, logistics and acquisitions interacting to determine whether growth becomes sustained cash generation after continued investment in the platform and its operations.
Controlled Businesses
Companies Currently Owned or Controlled
- Hims & Hers Health
| Company | Relationship | Role | Since |
|---|---|---|---|
| Hims & Hers Health | Founder with voting control | CEO and director | 2016 |
Control & Capital Allocation Analysis
The April 2026 ownership disclosure reports a striking gap between votes and ordinary economics. Dudum’s Class V shares carry 175 votes each, and the proxy placed his total voting power at 87.73%. We interpret that as effective founder control over shareholder voting while recognizing that it is not an ownership percentage for the company’s distributable value. A small number of supervoting shares can dominate governance without assigning the founder a corresponding share of sales, assets, earnings or proceeds from a corporate transaction.
The proxy reported 8,377,623 Class V shares associated with Dudum, alongside Class A interests and awards. Its beneficial-ownership presentation includes securities with different timing and exercise conditions. That is why a single headline share count does not represent exclusively unrestricted stock ready for sale. Governance analysis must distinguish the securities carrying votes, the underlying economic claims and the contractual limits that can affect transfer or conversion, rather than using the total as a simple current personal investment-account balance.
Trust-affiliated holdings also appear in the disclosure. Their presence matters because reporting aggregated beneficial ownership is not the same as saying every share is directly registered in Andrew Dudum’s own name. The voting structure nevertheless gives him a strong position relative to ordinary public investors. That concentration can support continuity through product and acquisition decisions, while reducing the ability of outside shareholders to change direction through a routine vote if they disagree with management’s capital allocation or strategic priorities.
Control does not remove the responsibilities of a public board or the constraints of operating in healthcare. Eucalyptus and YourBio bring businesses and technologies inside the group, but their operations remain subject to contractual and regulatory requirements. Dudum’s authority therefore should be judged alongside the outcomes produced for all shareholders. The November 2026 results demonstrate why that matters: rapid revenue growth and margin pressure can occur together, requiring accountability for economic performance even when the founder retains decisive voting rights and a long strategic horizon.
Minority Stakes, Investments & Brands
Brands, Products & Licensing
- HimsConsumer brand
- HersConsumer brand
- EucalyptusOperating subsidiary
- YourBio HealthTechnology subsidiary
- ZAVAOperating subsidiary
- LivewellOperating subsidiary
- Operating subsidiary 3
- Consumer brand 2
- Technology subsidiary 1
| Name | Type | Legal Owner or Relationship | Status |
|---|---|---|---|
| Hims | Consumer brand | Hims & Hers Health | Active |
| Hers | Consumer brand | Hims & Hers Health | Active |
| Eucalyptus | Operating subsidiary | Hims & Hers Health | Active |
| YourBio Health | Technology subsidiary | Hims & Hers Health | Active |
| ZAVA | Operating subsidiary | Hims & Hers Health | Active |
| Livewell | Operating subsidiary | Hims & Hers Health | Active |
Minority-Stake & Investment Analysis
The company’s 2026 acquisition program provides concrete evidence of capital allocation under Dudum’s leadership. YourBio’s January merger brought blood-sampling technology into the platform, while the June Eucalyptus purchase added international digital-health operations. We evaluate those commitments through the capabilities acquired and the cash obligations assumed. A strategically appealing business can still generate a poor investment result if the price, integration burden or required follow-on spending exceeds the earnings and customer value it contributes after acquisition.
Eucalyptus’ $968.5 million accounting purchase price included $225 million paid upfront, $683.9 million in deferred payments and $59.6 million of acquisition-date contingent consideration value. The structure spreads cash requirements over time rather than removing them. Deferred consideration can protect immediate liquidity while committing future resources that might otherwise fund operations or other investments. Its economic cost should therefore be assessed with timing and obligations attached, rather than presenting the upfront payment alone as the full amount used to buy the business.
YourBio’s $153 million accounting consideration similarly included $142.4 million cash and $10.6 million contingent consideration value. These transaction measures are different from Dudum’s personal investment amounts. The acquired technology must justify its place in the wider customer offering, with financial benefits emerging through execution rather than the closing announcement itself. A broader product proposition can increase retention or open new demand, but those outcomes remain operating objectives until reflected in actual business performance and cash conversion across the group.
Atomic’s venture-creation model forms part of Dudum’s investment background, although it does not supply a public schedule of all retained stakes. His current large-company decisions can be assessed more precisely through corporate filings. The third-quarter 2026 gross-margin decline is an important constraint on further deployment because growth consumes resources when product economics weaken. The financial proposition requires balancing acquisition spending, internal development and marketing with financial resilience, rather than treating each new capability or territory as automatically accretive to shareholder value.
Transactions, Acquisitions & Exits
Deal Activity Timeline
Deal size comparison
Bars share one scale. Only deals with a disclosed value are shown.
Acquisitions Led or Financed
| Acquisition | Year | Deal Value | Role | Outcome |
|---|---|---|---|---|
| Eucalyptus | 2026 | $968.5 million | Acquirer CEO | Completed |
| YourBio Health | 2026 | $153 million | Acquirer CEO | Completed |
Transaction & Exit Analysis
The 2021 public-market transaction gave Hims & Hers a traded equity structure without ending Dudum’s founder control. A listing can create liquidity opportunities while a founder continues operating the company. We distinguish that event from a complete sale of his stake: the continuing Class V structure and April 2026 voting disclosure show why public ownership and founder authority can coexist. Calling the listing a total founder exit would misrepresent both his ongoing role and the governance rights retained after the transaction.
Individual share sales are another form of realization, but they are not disposals of whole operating businesses. Insider trackers aggregate historical proceeds according to their own coverage, which can be incomplete or inconsistent across direct and trust holdings. A sale of ordinary stock can reduce economic exposure without proportionately reducing supervoting authority. The transaction’s significance therefore depends on which shares changed hands, the price and the remaining holdings, rather than a general assumption that any sale signals an end to Andrew Dudum’s control or confidence.
YourBio and Eucalyptus belong on the acquisition side of his corporate record. The 2026 transactions brought capabilities into the parent under his leadership; they did not distribute their purchase prices to him personally. The Eucalyptus deal’s deferred consideration also creates obligations after closing, making completion only the start of the ownership period. A successful transaction requires the acquired business to justify those commitments through performance, not merely the legal transfer of shares or inclusion in the consolidated group’s operating footprint.
TalkIQ and other Atomic-associated companies should not be assigned personal exit proceeds merely because Andrew Dudum worked on their creation within Atomic. The official biographies establish involvement without specifying his individual sale allocation. His documented liquidity story is consequently centered on the public company and securities transactions, while his transaction leadership includes major acquisitions that remain within that business. Any claimed founder payout or investment multiple needs shareholder-specific evidence before it can be separated from a deal value belonging to the corporation, the studio or other participating owners.
Wealth, Income & Financial Trends
Net Worth & Sources of Wealth
Net Worth
Oct-2026Annual Income
2023 to 2025- 2023$14,401,411
- 2024$24,609,077
- 2025$22,958,907
Wealth & Income Analysis
Quiver Quantitative’s October 28, 2026 calculation reported at least $222.9 million for Dudum, based on tracked holdings and historical insider sales. That is a limited securities-based calculation with important coverage weaknesses, rather than a full personal balance sheet. We would not interpret its headline as a comprehensive or precise measure of current wealth. Trust holdings, equity awards, historical sales, taxes and privately held assets can all make an aggregated tracker materially different from the founder’s actual attributable financial position.
The April proxy is more authoritative for its specified ownership date, but its beneficial-ownership count also requires care. It includes directly held interests, affiliated trusts and awards that may be exercisable or vest within the filing’s stated window. Adding all reported securities at a later share price without considering exercise costs, vesting or potential duplication can overstate realizable value. The 87.73% voting figure is even less suitable as a wealth multiplier because supervoting rights do not create an equal percentage of ordinary economic ownership.
Dudum’s 2025 total compensation was $22,958,907 in the company’s summary compensation disclosure. The comparable totals were $24,609,077 in 2024 and $14,401,411 in 2023. These figures include the accounting value of equity awards and should not be described as annual cash salary. The proxy separately presents a pay-versus-performance calculation, which is also not equivalent to money paid into his bank account. Using one consistent compensation series makes the changes interpretable without mixing several incompatible definitions of income.
Selling public shares can turn some exposure into cash while leaving voting control intact, depending on which securities are sold and the governing terms. Historical gross proceeds still do not equal retained wealth after tax or other uses of funds. Acquired businesses inside the parent also cannot be added separately to the value of Andrew Dudum’s stake. His wealth analysis therefore combines a clearly documented compensation record with uncertain tracker-based net worth, while the listed equity remains the principal disclosed source of changes in his business value.
Portfolio Development Over Time
Business Ownership Timeline
Business Trajectory Analysis
Dudum became Hims’ co-founder, CEO and director in 2016 after working through Atomic’s company-building process. The company’s later public listing changed the funding and reporting framework around that founder-led business. We see the shift as a transition from startup experimentation to a platform whose strategic decisions can be tested against recurring public disclosures. Continued voting control preserves leadership continuity, but shareholders can now compare expansion claims with revenue, margins, compensation and the financial obligations created by acquisitions over time.
The 2025 purchases of ZAVA and Livewell began a broader international expansion that continued through Eucalyptus’ June 2026 closing. YourBio’s earlier merger added a different capability in blood sampling. These steps moved the business beyond a simple collection of domestic consumer brands. They also increased integration demands, because different markets and technologies require local execution and operating coordination. The trajectory depends on whether the platform can use those capabilities coherently, rather than accumulating businesses that remain disconnected or require disproportionate management attention after purchase.
November 2026 results reported approximately $890 million in quarterly revenue and nearly 2.8 million subscribers, alongside reduced full-year adjusted EBITDA guidance. That combination makes operating quality a more useful next milestone than growth alone. The company’s 57% third-quarter gross margin was materially below the prior-year level, showing that sales expansion does not automatically translate into equivalent profit expansion. Acquisitions and product mix need to support a sustainable contribution after care, fulfillment and marketing costs, rather than simply a larger revenue base.
Andrew Dudum’s future capital-allocation record will be shaped by the interaction of these commitments. Deferred acquisition payments compete with internal investment, while new products and markets create additional execution needs. Maintaining customer trust and dependable access to care is central to preserving the recurring relationships on which the business depends. His supervoting structure gives substantial strategic latitude, but the enduring value of that control will be judged through cash generation, integration outcomes and returns attributable to the ordinary economic interests held alongside public shareholders.
Ownership Misconceptions Explained
Dudum owns 87.73% of Hims’ economic value.
The percentage in the April 2026 proxy measures voting power produced by Class V supervoting shares. Those shares receive 175 votes each. Voting authority and ordinary economic participation are different, so the governance percentage cannot be multiplied by company revenue or market capitalization to calculate his wealth.
Hims and Hers are two separately controlled public companies.
Hims and Hers are consumer brands beneath the same listed parent, Hims & Hers Health. They do not create two independent public-company holdings for Dudum. Group subsidiaries and acquired platforms likewise sit within the parent’s financial and governance structure rather than outside his listed stake.
All reported executive compensation is cash paid immediately.
The summary compensation table includes accounting values for equity awards as well as other compensation categories. Vesting, exercise conditions and stock-price changes can affect eventual realization. A reported total should not be treated as a cash salary or added again to shares already counted in ownership.
Acquisition purchase prices are personal payouts to Dudum.
YourBio and Eucalyptus were corporate acquisitions financed through the public company’s arrangements. Their accounting consideration measures the cost of acquiring businesses, including deferred and contingent elements. Dudum participates through his parent-company economic interest rather than receiving those purchase prices as individual transaction proceeds.
Frequently Asked Questions
What company does Andrew Dudum control?
Dudum controls Hims & Hers Health through a supervoting structure. The April 2026 proxy reported 87.73% total voting power. That governance figure is different from his economic ownership percentage, so it does not give him an equivalent proportion of the company’s profits or market capitalization.
Does Dudum personally own Eucalyptus and YourBio?
Hims & Hers acquired YourBio in January 2026 and completed its Eucalyptus acquisition in June 2026. They are businesses within the corporate group, not separate purchases held personally outside Dudum’s listed-company stake. Their purchase prices therefore cannot be added directly to his individual wealth.
Does Andrew Dudum own all Atomic portfolio companies?
Dudum helped co-found Atomic and develop ventures including Bungalow, Homebound, TalkIQ and Terminal. His official biography, current in 2026, does not provide a complete schedule of personal retained equity. Venture-building involvement alone does not establish current control or an individual stake in every studio company.
How much annual compensation does Dudum receive?
The 2026 proxy reports $22,958,907 of total compensation for 2025. That figure includes equity-award accounting values and is not equivalent to cash salary. Using the summary compensation total consistently avoids mixing it with share-sale proceeds or the separate pay-versus-performance disclosure calculation.
How reliable is Andrew Dudum’s published net worth?
Quiver’s October 2026 figure of at least $222.9 million uses tracked insider positions and historical sales. It is not a comprehensive personal balance sheet and may incompletely cover trusts or other interests. The proxy is stronger evidence for dated securities ownership, while current personal wealth remains a separate calculation.
